Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock par value $0.012 per share
-
Shares outstanding
-
41M
-
Number of holders
-
50
-
Total 13F shares, excl. options
-
2.28M
-
Shares change
-
-1.93M
-
Total reported value, excl. options
-
$8.15M
-
Value change
-
-$6.05M
-
Put/Call ratio
-
0.13
-
Number of buys
-
22
-
Number of sells
-
-36
-
Price
-
$3.58
Significant Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) as of Q2 2023
74 filings reported holding ORMP - ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share as of Q2 2023.
ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) has 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.28M shares
of 41M outstanding shares and own 5.55% of the company stock.
Largest 10 shareholders include BML Capital Management, LLC (850K shares), TWO SIGMA ADVISERS, LP (191K shares), GSA CAPITAL PARTNERS LLP (165K shares), BlackRock Inc. (98K shares), GOLDMAN SACHS GROUP INC (90.9K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (87.5K shares), MILLENNIUM MANAGEMENT LLC (78.6K shares), TWO SIGMA INVESTMENTS, LP (59.6K shares), STATE STREET CORP (55.3K shares), and JPMORGAN CHASE & CO (53.9K shares).
This table shows the top 50 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.